Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Effects of interleukin-2 in immunostimulation and immunosuppression
SHP-2 is also associated with a variety of diseases
which presents advantages for drug development targeting this receptor
Activity of the cytosolic enzyme is high in proliferating cells and peaks during the S-phase of the cell cycle
The intensity of the color is positively correlated with the amount of S100 Calcium Binding Protein A5 (S100A5) in the sample
ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control Effects of interleukin-2 in immunostimulationProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving
US$ 62.54
US$ 179.78
US$ 27.17
US$ 41.90
US$ 159.00
US$ 11.00
US$ 155.00
US$ 80.00
US$ 103.67